دورية أكاديمية
Biogenic silver nanoparticles eradicate of Pseudomonas aeruginosa and Methicillin-resistant Staphylococcus aureus (MRSA) isolated from the sputum of COVID-19 patients.
| العنوان: | Biogenic silver nanoparticles eradicate of Pseudomonas aeruginosa and Methicillin-resistant Staphylococcus aureus (MRSA) isolated from the sputum of COVID-19 patients. |
|---|---|
| المؤلفون: | Hawsawi NM; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia., Hamad AM; Department of Biology, College of Science, Tikrit University, Tikrit, Iraq., Rashid SN; Department of Physics, College of Science, Tikrit University, Tikrit, Iraq., Alshehri F; Department of Biology, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia., Sharaf M; Department of Biochemistry, Faculty of Agriculture, Al-Azhar University, Cairo, Egypt.; Department of Biochemistry and Molecular Biology, College of Marine Life Sciences, Ocean University of China, Qingdao, China., Zakai SA; Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia., Al Yousef SA; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafar Al Batin, Saudi Arabia., Ali AM; Department of Biology, Deanship of Preparatory Year, Shaqra University, Shaqra, Saudi Arabia., Abou-Elnour A; Department of Botany and Microbiology, Faculty of Science, Zagazig University, Zagazig, Egypt., Alkhudhayri A; Department of Biology, College of Science, University of Hafr Al Batin, Hafar Al Batin, Saudi Arabia., Elrefaei NG; Clinical Skills Laboratories, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia., Elkelish A; Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.; Department of Botany and Microbiology, Faculty of Science, Suez Canal University, Ismailia, Egypt. |
| المصدر: | Frontiers in microbiology [Front Microbiol] 2023 Apr 06; Vol. 14, pp. 1142646. Date of Electronic Publication: 2023 Apr 06 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101548977 Publication Model: eCollection Cited Medium: Print ISSN: 1664-302X (Print) Linking ISSN: 1664302X NLM ISO Abbreviation: Front Microbiol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Research Foundation |
| مستخلص: | In recent investigations, secondary bacterial infections were found to be strongly related to mortality in COVID-19 patients. In addition, Pseudomonas aeruginosa and Methicillin-resistant Staphylococcus aureus (MRSA) bacteria played an important role in the series of bacterial infections that accompany infection in COVID-19. The objective of the present study was to investigate the ability of biosynthesized silver nanoparticles from strawberries ( Fragaria ananassa L.) leaf extract without a chemical catalyst to inhibit Gram-negative P. aeruginosa and Gram-positive Staph aureus isolated from COVID-19 patient's sputum. A wide range of measurements was performed on the synthesized AgNPs, including UV-vis, SEM, TEM, EDX, DLS, ζ -potential, XRD, and FTIR. UV-Visible spectral showed the absorbance at the wavelength 398 nm with an increase in the color intensity of the mixture after 8 h passed at the time of preparation confirming the high stability of the FA-AgNPs in the dark at room temperature. SEM and TEM measurements confirmed AgNPs with size ranges of ∼40-∼50 nm, whereas the DLS study confirmed their average hydrodynamic size as ∼53 nm. Furthermore, Ag NPs. EDX analysis showed the presence of the following elements: oxygen (40.46%), and silver (59.54%). Biosynthesized FA-AgNPs (ζ = -17.5 ± 3.1 mV) showed concentration-dependent antimicrobial activity for 48 h in both pathogenic strains. MTT tests showed concentration-dependent and line-specific effects of FA-AgNPs on cancer MCF-7 and normal liver WRL-68 cell cultures. According to the results, synthetic FA-AgNPs obtained through an environmentally friendly biological process are inexpensive and may inhibit the growth of bacteria isolated from COVID-19 patients. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor AF declared a shared affiliation with the author MS at the time of review. (Copyright © 2023 Hawsawi, Hamad, Rashid, Alshehri, Sharaf, Zakai, Al Yousef, Ali, Abou-Elnour, Alkhudhayri, Elrefaei and Elkelish.) |
| References: | Diagn Microbiol Infect Dis. 2020 Dec;98(4):115199. (PMID: 32979617) Cell. 2021 Sep 16;184(19):4953-4968.e16. (PMID: 34492226) Molecules. 2021 May 19;26(10):. (PMID: 34069463) Molecules. 2019 Nov 30;24(23):. (PMID: 31801244) Nanomaterials (Basel). 2017 Jul 10;7(7):. (PMID: 28698511) Front Cell Infect Microbiol. 2021 Mar 17;11:641920. (PMID: 33816347) Heliyon. 2019 Apr 23;5(4):e01543. (PMID: 31049445) Int Immunopharmacol. 2015 Sep;28(1):616-25. (PMID: 26241783) Pathog Dis. 2013 Apr;67(3):159-73. (PMID: 23620179) Nanomaterials (Basel). 2017 Apr 07;7(4):. (PMID: 28387734) Biotechnol Rep (Amst). 2017 Feb 10;14:1-7. (PMID: 28459002) Emerg Infect Dis. 2020 Aug;26(8):1939-1941. (PMID: 32298228) Curr Res Microb Sci. 2021 Dec 29;3:100103. (PMID: 35024644) Diabetes Res Clin Pract. 2018 Feb;136:52-77. (PMID: 29196152) Curr Opin Infect Dis. 2022 Apr 1;35(2):149-162. (PMID: 35125396) Cureus. 2020 May 29;12(5):e8350. (PMID: 32617223) Antibiotics (Basel). 2022 Sep 15;11(9):. (PMID: 36140030) Am J Bot. 2014 Oct;101(10):1686-99. (PMID: 25326614) Zhonghua Yu Fang Yi Xue Za Zhi. 2015 Jun;49(6):567-70. (PMID: 26310346) ACS Appl Mater Interfaces. 2022 Jan 12;14(1):49-56. (PMID: 34978405) Sci Rep. 2017 Nov 20;7(1):15867. (PMID: 29158537) Microb Pathog. 2018 Mar;116:221-226. (PMID: 29407231) mBio. 2016 Dec 13;7(6):. (PMID: 27965455) Adv Healthc Mater. 2018 Jul;7(13):e1701503. (PMID: 29808627) J Infect. 2020 Aug;81(2):266-275. (PMID: 32473235) Antibiotics (Basel). 2022 Mar 18;11(3):. (PMID: 35326871) Front Microbiol. 2019 Apr 26;10:820. (PMID: 31110495) Front Microbiol. 2021 Sep 20;12:648560. (PMID: 34616370) Avicenna J Med Biotechnol. 2022 Jul-Sep;14(3):223-232. (PMID: 36061132) Infection. 2021 Aug;49(4):591-605. (PMID: 33709380) Materials (Basel). 2018 Jun 03;11(6):. (PMID: 29865278) Ann Intensive Care. 2020 Nov 23;10(1):158. (PMID: 33230710) Int J Nanomedicine. 2018 Nov 27;13:8013-8024. (PMID: 30568442) Infect Control Hosp Epidemiol. 2021 Sep;42(9):1156-1158. (PMID: 32843125) Front Immunol. 2018 Nov 16;9:2640. (PMID: 30505304) J AOAC Int. 2005 Sep-Oct;88(5):1269-78. (PMID: 16385975) Nanomaterials (Basel). 2021 Jan 04;11(1):. (PMID: 33406606) Nat Commun. 2020 Jun 16;11(1):3132. (PMID: 32546784) Colloids Surf B Biointerfaces. 2012 Oct 1;98:112-9. (PMID: 22705935) Nanomaterials (Basel). 2018 Dec 05;8(12):. (PMID: 30563095) Toxicol In Vitro. 2013 Feb;27(1):330-8. (PMID: 22940466) Adv Drug Deliv Rev. 2018 Nov - Dec;136-137:28-48. (PMID: 29248479) Acta Biomater. 2011 Jan;7(1):347-54. (PMID: 20709196) Molecules. 2021 Aug 20;26(16):. (PMID: 34443644) Pak J Pharm Sci. 2018 Jul;31(4):1423-1429. (PMID: 30033429) Open Biol. 2017 Sep;7(9):. (PMID: 28878043) PLoS One. 2019 Nov 8;14(11):e0224904. (PMID: 31703098) Microbiol Spectr. 2022 Aug 31;10(4):e0025022. (PMID: 35852338) Clin Exp Med. 2022 Aug;22(3):327-346. (PMID: 34424451) BMC Infect Dis. 2020 Sep 1;20(1):646. (PMID: 32873235) Cell Rep. 2021 Aug 31;36(9):109637. (PMID: 34433082) PLoS Pathog. 2013 Jan;9(1):e1003057. (PMID: 23326226) Med Microbiol Immunol. 2016 Dec;205(6):603-613. (PMID: 27620485) Cell Biosci. 2022 Feb 9;12(1):14. (PMID: 35139898) Molecules. 2022 Nov 17;27(22):. (PMID: 36432057) Mater Sci Eng C Mater Biol Appl. 2018 Oct 1;91:881-898. (PMID: 30033323) Arch Biochem Biophys. 1993 Jun;303(2):474-82. (PMID: 8390225) Iran J Pharm Res. 2013 Summer;12(3):289-98. (PMID: 24250635) |
| فهرسة مساهمة: | Keywords: COVID-19; antibacterial activity; anticancer activity; bio-reducing agents; biosynthetic AgNPs |
| تواريخ الأحداث: | Date Created: 20230505 Latest Revision: 20230507 |
| رمز التحديث: | 20230507 |
| مُعرف محوري في PubMed: | PMC10153441 |
| DOI: | 10.3389/fmicb.2023.1142646 |
| PMID: | 37143540 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-302X |
|---|---|
| DOI: | 10.3389/fmicb.2023.1142646 |